ImmunityBio licenses oral vaccine tech from IosBio

By The Science Advisory Board staff writers

January 12, 2021 -- ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.

OraPro is a patented oral delivery vaccine platform which enables the oral administration of thermally stable viral vector vaccines. The vectors are engineered to withstand temperatures of up to 50° C, allowing them to pass through the stomach without losing efficacy and providing long-term product stability at ambient temperatures. Oral administration of vaccines stimulates mucosal-associated lymphoid tissue to generate mucosal, systemic, and T-cell immune responses.

The hAd5 COVID-19 vaccine candidate has shown promising results in preclinical studies and is working with the U.S. Food and Drug Administration to initiate a phase I prime/boost clinical trial. So far, 20 participants have already been dosed with both low and high doses of the vaccine in a phase I trial with no serious adverse events.

Under the agreement, IsoBio has granted ImmunityBio exclusive rights to utilize the platform for ImmunityBio's COVID-19 vaccine. IsoBio will be eligible to receive royalties on net worldwide sales of the approved oral vaccine.

ImmunityBio uses Microsoft software to visualize SARS-CoV-2 spike protein
ImmunityBio has released results from a molecular dynamics simulation, conducted in collaboration with Microsoft, that provided a visualization of the...
ImmunityBio, NantKWest to merge
ImmunityBio and NantKWest have entered into an agreement to merge in a stock-for-stock transaction. The combination will create a new immunotherapy and...
ImmunityBio COVID-19 oral vaccine effective in nonhuman primates
ImmunityBio's COVID-19 vaccine candidate has been shown to protect nasal and lung airways of nonhuman primates against SARS-CoV-2 in preclinical studies.
ImmunityBio touts preclinical data on NK cell therapy boosting product
ImmunityBio has released preclinical data demonstrating that its lead cytokine infusion protein, Anktiva, an interleukin-15 "superagonist," improves interferon-gamma...
ImmunityBio COVID-19 vaccine shows positive clinical results
ImmunityBio has demonstrated that antigens from its bivalent adenovirus-based vaccine candidate are recognized by SARS-CoV-2 reactive human T cells in...

Copyright © 2021

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter